Literature DB >> 11378438

Substance p.

S Harrison1, P Geppetti.   

Abstract

This article provides a brief overview of the history of substance P from its discovery in the 1930s to the present day. The development of substance P receptor agonists and antagonists, and more recently the employment of transgenic mice, provide a framework to explore the functional role of substance P. Chronic inflammation and pain are associated with a number of diseases, and it has been proposed that substance P, released from primary afferent nerve endings play a role in these conditions. Recent developments with substance P antagonists have demonstrated the importance of substance P in several models of disease that span from asthma to chronic bronchitis; from cystitis, inflammatory bowel disease to migraine; emesis, depression, pain and seizures. Advancements in the knowledge of the role of substance P, its agonists and antagonists could provide clinical solutions for a variety of chronic inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378438     DOI: 10.1016/s1357-2725(01)00031-0

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  121 in total

1.  Detection of the full-length transcript variant for neurokinin-1 receptor in human whole blood associated with enhanced reinforcement of clot by substance-P.

Authors:  Toshiharu Azma; Yuki Sugimoto; Hiroyuki Kinoshita; Taishin Ito; Masanori Tsukamoto; Hiroshi Hoshijima; Masakazu Nakao; Hirosato Kikuchi
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

2.  A substance P antagonist improves outcome in female Sprague Dawley rats following diffuse traumatic brain injury.

Authors:  Frances Corrigan; Anna Leonard; Mounir Ghabriel; Corinna Van Den Heuvel; Robert Vink
Journal:  CNS Neurosci Ther       Date:  2012-06       Impact factor: 5.243

3.  Intraneuronal angiotensinergic system in rat and human dorsal root ganglia.

Authors:  Jaspal Patil; Alexander Schwab; Juerg Nussberger; Thomas Schaffner; Juan M Saavedra; Hans Imboden
Journal:  Regul Pept       Date:  2010-03-24

4.  Fluorescent tagging of rhythmically active respiratory neurons within the pre-Bötzinger complex of rat medullary slice preparations.

Authors:  Silvia Pagliardini; Tadafumi Adachi; Jun Ren; Gregory D Funk; John J Greer
Journal:  J Neurosci       Date:  2005-03-09       Impact factor: 6.167

Review 5.  Tachykinins and excitotoxicity in cerebellar granule cells.

Authors:  Cinzia Severini; Cristina Zona
Journal:  Cerebellum       Date:  2006       Impact factor: 3.847

6.  Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells.

Authors:  Margherita Gallicchio; Arianna Carolina Rosa; Elisa Benetti; Massimo Collino; Chiara Dianzani; Roberto Fantozzi
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

7.  Impact of physical activity on pain perception in an animal model of endometriosis.

Authors:  Siomara Hernandez; Myrella L Cruz; Annelyn Torres-Reveron; Caroline B Appleyard
Journal:  J Endometr Pelvic Pain Disord       Date:  2015-12-24

8.  Effects of sensory denervation by neonatal capsaicin administration on experimental pancreatitis induced by dibutyltin dichloride.

Authors:  Tsukasa Ikeura; Yosky Kataoka; Taketoshi Wakabayashi; Tetsuji Mori; Yasuharu Takamori; Shoichiroh Takamido; Kazuichi Okazaki; Hisao Yamada
Journal:  Med Mol Morphol       Date:  2007-09-18       Impact factor: 2.309

9.  The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.

Authors:  Miguel Muñoz; Marisa Rosso
Journal:  Invest New Drugs       Date:  2009-01-17       Impact factor: 3.850

10.  Direct activation of tachykinin receptors within baroreflex afferent pathway and neurocontrol of blood pressure regulation.

Authors:  Mei Yuan; Mei-Na Ma; Ting-Yu Wang; Yan Feng; Pei Chen; Chao He; Sijie Liu; Yun-Xia Guo; Yue Wang; Yao Fan; Lu-Qi Wang; Xiao-Qiang E; Guo-Fen Qiao; Bai-Yan Li
Journal:  CNS Neurosci Ther       Date:  2018-06-13       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.